322: A new threat to Merck's blockbuster cancer treatment, Moderna's cutbacks, and obesity drugs for kids
The Readout Loud
00:00
Uncertainty in Moderna's Future: Financial Struggles and Identity Crisis
This chapter explores Moderna's ongoing financial difficulties and identity crisis, revealing the contradiction of having $9 billion in cash while still facing operational deficits. It discusses the company's uncertain future as it navigates between vaccine production and drug development, particularly in relation to its mRNA-based cancer therapy.
Transcript
Play full episode
